SUZHOU, China, Sept. 30, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops high quality drugs, announced today that the first patient has been dosed
Growth Capitalist (https://growthcapitalist.com/2018/09/first-patient-dosed-in-a-phase-iii-trial-of-anti-pd-1-antibody-sintilimab-as-first-line-treatment-for-patients-with-advanced-squamous-non-small-cell-lung-cancer-2/)
SUZHOU, China, Sept. 30, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops high quality drugs, announced today that the first patient has been dosed